Emerging Markets Clinical Development Asia

Emerging Markets Clinical Development Asia

$995.00

This study is designed to address challenges and answer burning questions about conducting clinical trials in Asia. The report includes detailed data on China and India as well as information on trials in Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines.  Use the benchmarks, metrics and best practices to avoid common pitfalls and solidify your clinical trials in Asia.

  • Description
  • Additional information

REPORT HIGHLIGHTS

Emerging Markets Clinical Development in Asia

  • Publication Date: November 2010
  • Pages: 193
  • Chapters: 3
  • Metrics: 400+
  • Charts/Graphics: 120+
  • Profiles: 20

Breakdown of Chapters:

  • Chapter 1: China
  • Chapter 2: India
  • Chapter 3: Other Asia
Report Features

This study is an ideal resource designed to address the challenges and answer your most burning questions about conducting clinical trials in Asia. It provides detailed data on China and India as well as profiles of companies that are conducting trials in Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines. Learn the advantages and challenges that each of these countries presents. Use the benchmarks, metrics and best practices to avoid common pitfalls and solidify your clinical strategy.

Reason to Buy

Asia has a reputation for poor intellectual property protections, and this report uncovers the progress made in China, India and other Asian nations around IP protection. The report will also help you navigate regulations, healthcare infrastructure, costs and patient access. Tap into the best ratios of cost, quality and timelines while using local partners to navigate culture, communication and regulations.

Target Audience

Executives, directors, and managers involved in the following areas should consider purchasing this report:
– Clinical development
– Site/Trial Management
– Patient Recruitment
– Strategic planning groups
– Contract Research Organizations (CROs)
– Strategic Planning

Chapter Example

The impact of China’s economic reforms and rapid growth has affected its healthcare system. While the country’s prosperity has improved medical treatment for millions of citizens, some poorer communities are struggling to receive proper healthcare as the country transitions from the Cooperative Medical System (CMS) to a privatized, fee-for-service system.Private medical practice had been banned during the Cultural Revolution. But following that period and throughout the 1980s, China’s Ministry of Health and its State Council encouraged privatization. Yet it spread gradually throughout the country’s provinces. At first, Chinese physicians began part-time private practices at public health facilities. It wasn’t until the late 1990s or early 2000s that China began registering and licensing private medical practitioners. When the government began to dismantle the initial state-owned enterprises and rural healthcare programs, such as “barefoot doctors” — farmers who received basic medical training — there were little to no alternatives in place to handle the medical need.The transition to privatization has led to confusion and challenges for finding medical treatment in poor communities. Many public health facilities that used to provide medical care to poor populations have transitioned to fee-for-service institutions; in some cases, the transition has occurred overnight, leaving whole populations unable to afford the same level of medical care.